{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:36:15Z","timestamp":1790706975941,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2023C03073"],"award-info":[{"award-number":["2023C03073"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972374"],"award-info":[{"award-number":["81972374"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-024-01563-z","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T04:02:57Z","timestamp":1724904177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Analysis of risk factors for persistent PSA after radical prostatectomy: results from a high-volume center in Southeast China"],"prefix":"10.1186","volume":"24","author":[{"given":"Sida","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"1563_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1563_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"1563_CR3","doi-asserted-by":"crossref","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R et al. Cancer incidence and mortality in China, 2022. Journal of the National Cancer Center [Internet]. 2024 [cited 2024 Mar 18]; https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2667005424000061","DOI":"10.1016\/j.jncc.2024.01.006"},{"key":"1563_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7:9.","journal-title":"Nat Rev Dis Primers"},{"key":"1563_CR5","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2023;21:1067\u201396.","journal-title":"J Natl Compr Canc Netw"},{"key":"1563_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243\u201362.","journal-title":"Eur Urol"},{"key":"1563_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/JU.0000000000002758","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, et al. Clinically localized prostate Cancer: AUA\/ASTRO Guideline, Part II: principles of active surveillance, principles of surgery, and Follow-Up. J Urol. 2022;208:19\u201325.","journal-title":"J Urol"},{"key":"1563_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2019.01.048","volume":"76","author":"F Preisser","year":"2019","unstructured":"Preisser F, Chun FKH, Pompe RS, Heinze A, Salomon G, Graefen M, et al. Persistent prostate-specific Antigen after Radical Prostatectomy and its impact on oncologic outcomes. Eur Urol. 2019;76:106\u201314.","journal-title":"Eur Urol"},{"key":"1563_CR9","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3390\/cancers13050948","volume":"13","author":"S Kimura","year":"2021","unstructured":"Kimura S, Urabe F, Sasaki H, Kimura T, Miki K, Egawa S. Prognostic significance of prostate-specific Antigen persistence after radical prostatectomy: a systematic review and Meta-analysis. Cancers (Basel). 2021;13:948.","journal-title":"Cancers (Basel)"},{"key":"1563_CR10","doi-asserted-by":"crossref","unstructured":"Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, St\u00f6ckle M, et al. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96\u2009\u2013\u200902 trial. International journal of radiation oncology, biology, physics [Internet]. 2015 [cited 2024 Mar 25];91. https:\/\/pubmed.ncbi.nlm.nih.gov\/25445556\/","DOI":"10.1016\/j.ijrobp.2014.09.039"},{"key":"1563_CR11","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.juro.2013.04.073","volume":"190","author":"G Ploussard","year":"2013","unstructured":"Ploussard G, Staerman F, Pierrevelcin J, Saad R, Beauval J-B, Roupret M, et al. Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy. J Urol. 2013;190:1750\u20136.","journal-title":"J Urol"},{"key":"1563_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.urology.2017.07.009","volume":"108","author":"SL Skove","year":"2017","unstructured":"Skove SL, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, et al. Timing of prostate-specific Antigen Nadir after Radical Prostatectomy and risk of biochemical recurrence. Urology. 2017;108:129\u201334.","journal-title":"Urology"},{"key":"1563_CR13","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.eururo.2015.12.010","volume":"69","author":"L Bianchi","year":"2016","unstructured":"Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, et al. The role of prostate-specific Antigen Persistence after Radical Prostatectomy for the prediction of clinical progression and Cancer-specific mortality in node-positive prostate Cancer patients. Eur Urol. 2016;69:1142\u20138.","journal-title":"Eur Urol"},{"key":"1563_CR14","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.3390\/cancers13102453","volume":"13","author":"D Milonas","year":"2021","unstructured":"Milonas D, Venclovas Z, Sasnauskas G, Ruzgas T. The significance of prostate specific Antigen persistence in prostate Cancer risk groups on long-term oncological outcomes. Cancers (Basel). 2021;13:2453.","journal-title":"Cancers (Basel)"},{"key":"1563_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.juro.2006.03.086","volume":"176","author":"S Sengupta","year":"2006","unstructured":"Sengupta S, Christensen CM, Zincke H, Slezak JM, Leibovich BC, Bergstralh EJ, et al. Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance. J Urol. 2006;176:559\u201363.","journal-title":"J Urol"},{"key":"1563_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ajur.2022.01.002","volume":"10","author":"S Wu","year":"2023","unstructured":"Wu S, Lin SX, Cornejo KM, Crotty RK, Blute ML, Dahl DM, et al. Clinicopathological and oncological significance of persistent prostate-specific antigen after radical prostatectomy: a systematic review and meta-analysis. Asian J Urol. 2023;10:317\u201328.","journal-title":"Asian J Urol"},{"key":"1563_CR17","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.7150\/jca.29714","volume":"10","author":"JK Kim","year":"2019","unstructured":"Kim JK, Jeong CW, Ku JH, Kim HH, Kwak C. Prostate specific antigen (PSA) persistence 6 weeks after radical prostatectomy and pelvic lymph node dissection as predictive factor of radiographic progression in node-positive prostate cancer patients. J Cancer. 2019;10:2237\u201342.","journal-title":"J Cancer"},{"key":"1563_CR18","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.eururo.2017.06.001","volume":"72","author":"G Gandaglia","year":"2017","unstructured":"Gandaglia G, Boorjian SA, Parker WP, Zaffuto E, Fossati N, Bandini M, et al. Impact of postoperative Radiotherapy in men with persistently elevated prostate-specific Antigen after radical prostatectomy for prostate Cancer: a long-term survival analysis. Eur Urol. 2017;72:910\u20137.","journal-title":"Eur Urol"},{"key":"1563_CR19","first-page":"2037","volume":"109","author":"B Chahal","year":"2023","unstructured":"Chahal B, Aydin A, Amin MSA, Khan A, Khan MS, Ahmed K, et al. The learning curves of major laparoscopic and robotic procedures in urology: a systematic review. Int J Surg. 2023;109:2037\u201357.","journal-title":"Int J Surg"},{"key":"1563_CR20","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(22)00190-5","volume":"23","author":"A Zapatero","year":"2022","unstructured":"Zapatero A, Guerrero A, Maldonado X, \u00c1lvarez A, San-Segundo CG, Rodr\u00edguez M\u00c1C, et al. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01\/05): 10-year results of a phase 3 randomised, controlled trial. Lancet Oncol. 2022;23:671\u201381.","journal-title":"Lancet Oncol"},{"key":"1563_CR21","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/s41391-017-0009-6","volume":"21","author":"RR McKay","year":"2018","unstructured":"McKay RR, Montgomery B, Xie W, Zhang Z, Bubley GJ, Lin DW, et al. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis. 2018;21:364\u201372.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1563_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s12094-021-02700-y","volume":"24","author":"D Milonas","year":"2022","unstructured":"Milonas D, Laenen A, Venclovas Z, Jarusevicius L, Devos G, Joniau S. Benefits of early salvage therapy on oncological outcomes in high-risk prostate cancer with persistent PSA after radical prostatectomy. Clin Transl Oncol. 2022;24:371\u20138.","journal-title":"Clin Transl Oncol"},{"key":"1563_CR23","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1007\/s12094-017-1812-1","volume":"20","author":"S Garc\u00eda-Barreras","year":"2018","unstructured":"Garc\u00eda-Barreras S, Rozet F, Nunes-Silva I, Srougi V, Sanchez-Salas R, Barret E, et al. Predictive factors and the important role of detectable prostate-specific antigen for detection of clinical recurrence and cancer-specific mortality following robot-assisted radical prostatectomy. Clin Transl Oncol. 2018;20:1004\u201310.","journal-title":"Clin Transl Oncol"},{"key":"1563_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000488536","volume":"101","author":"C Xiang","year":"2018","unstructured":"Xiang C, Liu X, Chen S, Wang P. Prediction of biochemical recurrence following Radiotherapy among patients with persistent PSA after Radical Prostatectomy: a single-center experience. Urol Int. 2018;101:47\u201355.","journal-title":"Urol Int"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01563-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-024-01563-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01563-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T04:06:09Z","timestamp":1724904369000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-024-01563-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1563"],"URL":"https:\/\/doi.org\/10.1186\/s12894-024-01563-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4311475\/v1","asserted-by":"object"}]},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"assertion":[{"value":"23 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of The First Affiliated Hospital of Zhejiang University School of Medicine. The ethics committee of The First Affiliated Hospital of Zhejiang University School of Medicine waived the need for Informed Consent due to the retrospective nature of the study. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}